Literature DB >> 12107271

Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells.

Mitsutoshi Tamura1, Siby Sebastian, Bilgin Gurates, Sijun Yang, Zongjuan Fang, Serdar E Bulun.   

Abstract

We investigated the effects of vascular endothelial growth factor (VEGF) on cyclooxygenase-2 (COX-2) expression and prostaglandin E(2) (PGE(2)) synthesis in human microvascular endothelial cells (HMEC-1). Treatment of HMEC-1 with VEGF resulted in a dose- and time-dependent up-regulation of COX-2 mRNA and protein levels. This up-regulation was accompanied by a 1.6-fold increase in PGE(2) synthesis. Pretreatment of HMEC-1 with a selective COX-2 inhibitor, NS-398, abolished VEGF-induced PGE(2) synthesis, suggesting specific up-regulation of COX-2 activity by VEGF in HMEC-1. Transient transfection assays using deletion mutants of the human COX-2 promoter fused to the luciferase reporter gene indicated critical requirement of a regulatory region spanning -828/-123 bp for VEGF induction of COX-2 promoter activity in HMEC-1. Site-directed mutation analysis demonstrated that a GATA cis-acting element at -685/-680 bp was essential for VEGF- induced COX-2 promoter activity in HMEC-1. These observations are of particular importance given the recent demonstrations of critical requirement of COX-2 isoenzyme for tumor growth and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107271     DOI: 10.1210/jcem.87.7.8796

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output.

Authors:  M E Miller; A C Holloway; W G Foster
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice.

Authors:  Toshio Watanabe; Kazuhide Higuchi; Koichi Taira; Eiji Sasaki; Masatsugu Shiba; Kazunari Tominaga; Yasuhiro Fujiwara; Nobuhide Oshitani; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 4.  Endometriosis.

Authors:  Serdar E Bulun; Bahar D Yilmaz; Christia Sison; Kaoru Miyazaki; Lia Bernardi; Shimeng Liu; Amanda Kohlmeier; Ping Yin; Magdy Milad; JianJun Wei
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

5.  NFAT and CREB regulate Kaposi's sarcoma-associated herpesvirus-induced cyclooxygenase 2 (COX-2).

Authors:  Neelam Sharma-Walia; Arun George Paul; Kinjan Patel; Karthic Chandran; Waseem Ahmad; Bala Chandran
Journal:  J Virol       Date:  2010-10-13       Impact factor: 5.103

6.  Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?

Authors:  A S Tarnawski; J Chai; R Pai; S K Chiou
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

7.  Role of COX-2 in microcirculatory disturbance in experimental pancreatitis.

Authors:  Wen-Wei Yan; Zong-Guang Zhou; You-Dai Chen; Hong-Kai Gao
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 8.  Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications.

Authors:  Andrzej S Tarnawski; Michael K Jones
Journal:  J Mol Med (Berl)       Date:  2003-09-06       Impact factor: 4.599

9.  Several transcription factors regulate COX-2 gene expression in pancreatic beta-cells.

Authors:  Xiongfei Zhang; Jingjing Zhang; Xiaomin Yang; Xiao Han
Journal:  Mol Biol Rep       Date:  2007-05-16       Impact factor: 2.316

10.  Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen.

Authors:  Akulapalli Sudhakar; Chandra S Boosani
Journal:  Gene Regul Syst Bio       Date:  2007-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.